Stock.adobe.comAstraZeneca announced plans to harmonize its share listing structure across its global presence.1 The company issued a statement announcing the plans and recommended a harmonized listing structure across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange. Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca’s exciting future.”The move will require AstraZeneca to upgrade its existing US shares and replacing them with direct shares. This will allow the shares to be traded across the three major global listing exchanges. The announcement comes as AstraZeneca is sharing positive news about one of its lead assets, Enhertu. Receiving Priority Review moves us closer to offering Enhertu to patients even earlier in the metastatic treatment pathway as a potential new first-line treatment option.”Sources